This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
GW Pharmaceuticals Limited
GW Pharmaceuticals Limited, a pioneering biopharmaceutical company headquartered in Great Britain, has established itself as a leader in the cannabis-based medicine industry. Founded in 1998, the company has made significant strides in developing innovative therapies derived from cannabis, particularly for neurological conditions. With a strong focus on research and development, GW Pharmaceuticals is renowned for its flagship product, Epidiolex, the first FDA-approved cannabidiol (CBD) medication for epilepsy. This groundbreaking achievement underscores the company's commitment to advancing cannabinoid science and improving patient outcomes. Operating primarily in Europe and North America, GW Pharmaceuticals has garnered a notable market position, recognised for its rigorous clinical trials and regulatory compliance. As the industry evolves, GW continues to set benchmarks in the therapeutic use of cannabis, solidifying its reputation as a trusted name in the biopharmaceutical sector.
DitchCarbon Score
How does GW Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GW Pharmaceuticals Limited's score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GW Pharmaceuticals Limited's reported carbon emissions
GW Pharmaceuticals Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Jazz Pharmaceuticals plc, which may influence its climate commitments and reporting practices. As of now, GW Pharmaceuticals has not established any documented reduction targets or specific climate pledges. The lack of emissions data and reduction initiatives suggests that the company may be in the early stages of developing its climate strategy or may rely on the broader commitments of its parent company, Jazz Pharmaceuticals plc. Given the context of the pharmaceutical industry, it is essential for companies like GW Pharmaceuticals to align with industry standards and best practices in climate action. This includes potentially adopting science-based targets and engaging in initiatives that promote sustainability and carbon footprint reduction. In summary, while GW Pharmaceuticals Limited does not currently provide specific emissions data or reduction targets, its affiliation with Jazz Pharmaceuticals plc may play a role in shaping its future climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GW Pharmaceuticals Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
